| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Acticor Biotech SA
PAR:ALACT
Acticor Biotech SA
Operating Income
Acticor Biotech SA
Operating Income Peer Comparison
VLA
NANO
IPH
ABVX
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
A
|
Acticor Biotech SA
PAR:ALACT
|
Operating Income
-€16.7m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
-72%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Operating Income
-€126.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nanobiotix SA
PAR:NANO
|
Operating Income
-€26.8m
|
CAGR 3-Years
10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-13%
|
|
|
Innate Pharma SA
PAR:IPH
|
Operating Income
-€12.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-16%
|
|
G
|
Genfit SA
PAR:GNFT
|
Operating Income
-€26.7m
|
CAGR 3-Years
30%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-10%
|
|
|
Abivax SA
PAR:ABVX
|
Operating Income
-€127.4m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
See Also
What is Acticor Biotech SA's Operating Income?
Operating Income
-16.7m
EUR
Based on the financial report for Jun 30, 2023, Acticor Biotech SA's Operating Income amounts to -16.7m EUR.
What is Acticor Biotech SA's Operating Income growth rate?
Operating Income CAGR 5Y
-72%
Over the last year, the Operating Income growth was -24%. The average annual Operating Income growth rates for Acticor Biotech SA have been -68% over the past three years , -72% over the past five years .
You don't have any saved screeners yet
